Tenaya Therapeutics Partners with Alnylam in $1.13B Cardiovascular Gene Target Collaboration

Tenaya Therapeutics (NASDAQ: TNYA) announced a research collaboration with Alnylam Pharmaceuticals (NASDAQ:
ALNY) on March 5, 2026, to identify and validate up to 15 gene targets for cardiovascular diseases.1 2 3

Tenaya will receive up to $10 million in upfront payments, plus reimbursement for costs over a two-year validation term, and potential milestone payments totaling up to $1.13 billion if targets lead to approved therapeutics.1 2 3 5

Alnylam will handle all development and commercialization of therapeutics from the validated targets.1 2 3

The deal combines Tenaya's target identification and validation expertise with Alnylam's RNAi therapeutics leadership to advance potential disease-modifying heart treatments.1 2 4